全球环氧合酶 1 抑制剂市场 – 行业趋势和 2031 年预测

环氧合酶 1 抑制剂市场分析和规模

1991 年，西蒙斯和他的同事发现了第二种环氧合酶，即环氧合酶-2，它来自与环氧合酶-1 不同的基因。关于 COX 1 抑制剂使用的研究日益增多，以及先进的技术特征是全球环氧合酶 1 抑制剂市场增长的主要原因。此外，癌症病例和神经炎症疾病的增多也可以促进该市场的增长。                    

Data Bridge Market Research 分析，2023 年全球环氧合酶 1 抑制剂市场规模为 700.0012 亿美元，预计到 2031 年将达到 1201.4542 亿美元，预计在 2024 年至 2031 年的预测期内复合年增长率为 7.00%。由于对环氧合酶 1 抑制剂的需求不断增长，“干”在市场产品类型细分市场中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

环氧合酶 1 抑制剂市场范围和细分

Market Definition

Cyclooxygenase 1 inhibitors are a kind of non-steroidal anti-inflammatory drugs. Cyclooxygenase 1 is a type of enzyme that is primarily responsible for pain and inflammation. They are mainly responsible for the production of prostaglandins. The induction of COX2 during inflammation has caused the development of several nonselective therapeutic COX1 and COX2 inhibitors that include ibuprofen, ketoprofen, flurbiprofen, and fenoprofen.

Global Cyclooxygenase 1 Inhibitor Market Dynamics

Drivers

• Increasing Prevalence of Cancer

According to Cancer.org, men tend to have a 1 in 23 lifetime risk of having cancer, on the other hand, women have a 1 in 25. Cancer is the third most common cause of mortality in men and the second most common cancer in women. Around 1.8 million new cases were observed in 2018. Around 39% of cases are diagnosed at an early stage. The 5-year survival rate is nearly 71% if cancer locates to neighboring tissues, organs, or regional lymph nodes. Thus, this factor boosts the market growth.

• Increasing Healthcare Expenditure and Government Support

With the rising prevalence of cancer, the growing awareness for the disease and related treatment is also expanding. Government initiatives tend to offer better and more feasible treatments combined with favorable reimbursement policies which are expected to increase the industry growth. Moreover, increasing acceptance of advanced therapies such as Erbitux, Avastin, and Stivarga is expected to drive the market.

• Expanding Applications in Pain Management

COX-1 inhibitors play a crucial role in pain management, contributing to their prominence in the pharmaceutical market. Their effectiveness in alleviating various types of pain, including post-operative pain and chronic pain conditions, propels their widespread utilization. These inhibitors work by blocking the action of COX-1 enzymes, reducing the production of inflammatory mediators responsible for pain and discomfort. Their role in pain management extends across diverse medical specialties, making them an integral component of pain treatment regimens in orthopedics, neurology, and post-operative care. Their proven efficacy and established safety profile in managing pain position them as indispensable medications in the field of pain management, contributing significantly to their market growth.

Opportunities

• Personalized Medicine and Targeted Therapy

The shift toward personalized medicine and targeted therapies provides an opportunity to leverage COX-1 inhibitors in tailored treatment approaches. Advancements in genetic profiling and biomarker identification enable the identification of patient populations that might benefit most from COX-1 inhibitor therapy. Stratifying patients based on genetic predispositions or specific molecular profiles allows for more precise and targeted treatment strategies. Tailoring COX-1 inhibitor therapies to individual patient characteristics could improve treatment efficacy and minimize adverse effects, aligning with the trend toward personalized healthcare.

• Expanding Therapeutic Applications

Exploring new therapeutic applications for COX-1 inhibitors presents a promising opportunity in the market. While traditionally used for managing inflammation and pain, ongoing research investigates the potential of COX-1 inhibitors in other disease areas. Studies examining their role in cancer prevention, neuroprotection, and cardiovascular diseases offer avenues for expanding their therapeutic scope. Identifying and harnessing these novel applications may open new markets and avenues for COX-1 inhibitors, broadening their utility beyond traditional indications.

Restraints/Challenges

• Adverse Effects and Safety Concerns

Despite their therapeutic benefits, COX-1 inhibitors are associated with certain adverse effects and safety concerns, posing a significant restraint in their market growth. Prolonged use of these inhibitors may lead to gastrointestinal complications such as ulcers, bleeding, and perforation due to their interference with prostaglandin synthesis. The inhibition of COX-1 enzymes, responsible for maintaining gastric mucosal integrity, contributes to these adverse effects.

• Patent Expirations and Generic Competition

The market for COX-1 inhibitors faces challenges due to patent expirations of key medications, leading to the entry of generic versions. The loss of patent exclusivity exposes original drug manufacturers to competition from generic drug manufacturers offering lower-cost alternatives. This scenario significantly impacts the revenue potential of branded COX-1 inhibitors, leading to market erosion and reduced profitability for originators.

本环氧合酶 1 抑制剂市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关环氧合酶 1 抑制剂市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

近期发展

• 2022 年 5 月，雷迪博士实验室在美国市场推出了 10 毫克酮咯酸氨丁三醇片 USP。10 毫克酮咯酸氨丁三醇片是一种非甾体抗炎药，用于短期治疗中度至重度急性疼痛

全球环氧合酶 1 抑制剂市场范围

环氧合酶 1 抑制剂市场根据应用、类型、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

应用

• 炎症性疾病
• 胃肠道毒性
• 其他的

类型

• 选择性 Cox 1 抑制剂
• 非选择性 Cox 1 抑制剂

最终用户

• 医院
• 家庭护理
• 专科诊所
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

全球环氧合酶 1 抑制剂市场区域分析/见解

对环氧合酶 1 抑制剂市场进行了分析，并按国家、应用、类型、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。

市场报告涉及的国家包括美国、加拿大、墨西哥、德国、意大利、英国、法国、西班牙、荷兰、比利时、瑞士、土耳其、俄罗斯、欧洲其他地区、日本、中国、印度、韩国、澳大利亚、新加坡、马来西亚、泰国、印度尼西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区。

由于各国研发支出的增加、政府举措的增多以及医疗保健基础设施的改善，预计北美将占据市场主导地位。

由于政府对医疗保健领域的支出不断增加以及政府的技术进步和举措不断推进，预计亚太地区在 2024 年至 2031 年的预测期内将呈现最高的市场增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

环氧合酶 1 抑制剂市场还为您提供每个国家/地区资本设备医疗保健支出增长、环氧合酶 1 抑制剂市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对环氧合酶 1 抑制剂市场的影响的详细市场分析。数据适用于 2011-2021 年的历史时期。

竞争格局和全球环氧合酶 1 抑制剂市场份额分析

环氧合酶 1 抑制剂市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对环氧合酶 1 抑制剂市场的关注有关。

环氧合酶 1 抑制剂市场的一些主要参与者是：

• Jsn Technologies（英国）
• 勃林格殷格翰国际有限公司 (德国)
• 拜耳公司（德国）
• Sabinsa（美国）
• 卡迪拉制药。 （印度）
• Mylan NV（美国）
• Alembic Pharmaceuticals Limited（印度）
• Zydus 集团 (印度)
• Aurobindo Pharma（印度）
• Cipla Inc.（美国）
• Torrent Pharmaceuticals Ltd (印度)
• Abbvie, Inc（美国）
• 诺华公司（瑞士）
• 梯瓦制药工业有限公司 (以色列)
• 辉瑞公司 (美国)
• Hikma Pharmaceuticals PLC（英国）

SKU-52884